This week on H-SPAN, we sat down with Brian Cole, a state representative from New Hampshire who has recently announced his candidacy for the U.S. House of Representatives.
In this episode, we discuss Brian’s introduction to politics, what the government can do to advance aging research, and how New Hampshire is poised to emerge as the next state to embrace longevity science.
The Alliance for Longevity Initiatives (A4LI) is a 501(c)(4) nonprofit organization whose mission is to advance legislation and policies that aim to increase healthy human lifespan, with a focus on accelerating equitable access to next-generation therapies.
Representing California's 15th District since January 2023, Congressman Kevin Mullin is currently in his second term. He serves on the House Committee on Energy and Commerce, where he is a member of the Subcommittees on Energy and on Commerce, Manufacturing, and Trade. His legislative focus often bridges his experience in state government with federal policy, particularly regarding climate resilience and economic innovation within the Silicon Valley and San Mateo County regions.
Congressman Glenn Grothman has represented Wisconsin's 6th District since January 2015, marking 11 years of service in the House. He holds a significant leadership role as a senior member of the House Committee on Oversight and Accountability, where he chairs the Subcommittee on National Security, the Border, and Foreign Affairs. Additionally, he sits on the Committee on Education and the Workforce and the Committee on the Budget, positions he uses to advocate for fiscal responsibility and streamlined federal operations.
Congresswoman Lori Trahan has represented Massachusetts' 3rd District since January 2019, now in her seventh year of office. She is a member of the influential House Committee on Energy and Commerce, where she sits on three key subcommittees: Health; Commerce, Manufacturing, and Trade; and Oversight and Investigations. Beyond her committee work, she holds leadership roles within the Democratic caucus, focusing on policies that impact public health, digital privacy, and economic competitiveness for her constituents in the Merrimack Valley.
As the chief operating officer for Life Biosciences, Dr. Michael Ringel oversees corporate strategy, market intelligence, business development and investor and public relations. Prior to joining Life Bio, Michael was Managing Director and Senior Partner at Boston Consulting Group (BCG), where he worked for 25+ years, and served in various roles including as the global topic leader for Research and Product Development. He is on the Board of Hevolution Foundation US, the charitable organization focused on extending healthy aging for the benefit of all humanity, and the Board of American Federation for Aging Research, one of the oldest organizations supporting healthy aging through biomedical research. Dr. Ringel holds a B.A. in biology from Princeton University (summa cum laude), a Ph.D. in biology from Imperial College (NSF and Fulbright Fellowships), and a J.D. from Harvard Law School (cum laude).
Ali Siam has a unique combination of operating and strategy experience. He was previously CBO at Celmatix, where he led the team to multi-target R&D collaborations with Evotec SE and Bayer AG, and supported the development of their corporate and portfolio strategy. Prior to Celmatix, he led corporate strategy, R&D prioritization, portfolio strategy, and due diligence engagements for biopharma, diagnostic, healthcare services, and institutional investor clients across therapeutic areas (TAs) as a team leader at L.E.K. Consulting. He also led collaborations in a whitespace team at AbbVie, in addition to developing go-to-market, launch, and lifecycle management strategy across TAs. Ali also has strategic marketing and R&D experience from his time at Johnson & Johnson, and holds an MBA from Boston College and a BS in Mechanical Engineering from Northeastern University.
Michael W. Hodin, Ph.D. is CEO of the Global Coalition on Aging, Managing Partner at High Lantern Group, and a Fellow at Oxford University's Harris Manchester College. He has spoken internationally on the topic of aging, including at G20, APEC, Davos, and the World Knowledge Forum (WKF). He is also a blogger on Medium. From 1976-80, Mike was Legislative Assistant to Senator Daniel Patrick Moynihan. During this period he was also a Visiting Scholar at Brookings Institution, on U.S. Foreign Economic Policy. He was a senior executive at Pfizer, Inc. for 30 years, where he created and then led its International Public Affairs and Public Policy operations and served on Management Boards for a number of its businesses. Mike is a Member of the Council on Foreign Relations, and from 2010-2013, was Adjunct Senior Fellow with a focus on population aging. In 2013, Mike was invited by then-Committee Chairman Bill Nelson (D-FL) to lead a Members' Roundtable with the U.S. Senate Special Committee on Aging. Mike was also the recipient of the 2012 Fred D. Thompson Award from the American Federation for Aging Research. He sits on the Boards of the Foreign Policy Association, Business Council for International Understanding, NYC Blood Center, American Skin Association, American Federation for Aging Research and Emigrant Savings Bank, where he is Chairman of its compensation committee. Mike was a member of the World Economic Forum's Global Agenda Council on Ageing. And he sits on the Advisory Board for the Milken Institute Center for the Future of Aging. Mike holds a BA, cum laude, Cornell University, M.Sc.in International Relations from The London School of Economics and Political Science, and M.Phil and Ph.D. in Political Science from Columbia University.
Catherine Kaczorowski, PhD, is a Professor at The University of Michigan and the Elinor Levine Endowed Chair for Dementia Research. Dr. Kaczorowski is a neurophysiologist, an expert in the systems genetics of 'normal' nonpathological Aging and pathogenesis of neurodegenerative diseases including Alzheimer's disease (AD). She has been a driving force in uncovering and describing the phenomenon of cognitive resilience in the context of 'normal' nonpathological aging, AD and more recently Huntington's (HD) and Frontotemporal Dementia (FTD). She is a recognized authority in the development and application of mouse models for studies on aging and age-related neurodegenerative disorders, having pioneered the generation of the first translationally relevant polygenic model of human AD (AD-BXDs) published in Neuron. Her research program entails several collaborative, multisite projects and leverages the innovative, translational integration of multi-scale data (genetics, omics, imaging, behavior) from genetically diverse mouse strains and human patients to identify genetic mechanisms that promote cognitive resilience to normal brain aging, AD, and other age-related neurodegenerative diseases. Her team builds tools that permit dissection of aging specific genetic mechanisms from those controlling the clinical manifestations resulting from disease-specific neuropathologies, which is impossible in human populations. Her recent publications demonstrate the strength of her lab's mouse-to-human research translational workflow that continues to transform the field's ability to model resilience to normal age-related cognitive decline and AD. Taken together, these collaborative works set the foundation of the mouse genetic reference panel, the behavioral and electrophysiological assays for cognitive resilience, the systems genetics and cross-species computational analysis pipeline, and cell type-specific and regional signatures of resilience that are integral to the development of resilience-based therapies to delay or prevent cognitive aging and neurodegenerative dementias.
Dr. Viviana Perez Montes, Ph.D., is the Director of the Division of Aging Biology (DAB) at the National Institute on Aging (NIA), where she oversees strategic research into the molecular, genetic, and physiological mechanisms of aging. With over 20 years of experience across academia, government, and the private sector, Dr. Perez is a renowned leader in the field of geroscience. Prior to her current appointment in early 2025, she served as the Vice President of Geroscience at the Hevolution Foundation, managing multi-million-dollar initiatives to extend human healthspan. Her previous tenure at the NIA included serving as a Program Director and a leader for the NIH Common Fund Cellular Senescence Network (SenNet). In addition to her administrative leadership, Dr. Perez has a distinguished background in academic research. She was a tenured Associate Professor at Oregon State University and a Principal Investigator at the Linus Pauling Institute, where her work focused on proteostasis, free radicals, and the biological drivers of longevity. Her research specifically examines cellular senescence and the mechanisms of interventions like rapamycin in mitigating age-related diseases such as Alzheimer's and osteoporosis. Dr. Perez earned her Ph.D. in Biomedical Sciences and her bachelor's degree in Chemical and Pharmaceutical Science from the University of Chile, later completing her postdoctoral training at the Barshop Institute for Aging and Longevity Studies. Throughout her career, she has remained dedicated to bridging the gap between laboratory discovery and clinical application to improve the lives of the aging population.
Over 15 years working on Parkinson's disease. Founding CEO at NeuroInitiative since 2014 where she laid out a vision for applying advanced computational drug discovery methods which led to creation of Vincere Biosciences where she is also CEO. Previously she worked with Matt Farrer at Mayo clinic to characterize genetic models of Parkinson's disease and was part of the team that discovered a new pathogenic mutation in VPS35. Her PhD work implemented cutting edge laser capture, microarray, and in vivo siRNA techniques to identify protective genomic changes in Parkinson's models. Recipient of JBJ's 40 under 40 award, winner of One Spark's science award, and supporter of science on the TEDx and March for Science stages.
Kristen has served as Chief Executive Officer and board member of BioAge since co-founding the company in 2015. Kristen is a scientifically trained biotech executive with extensive experience building discovery platforms, building teams, fundraising, and scientific & clinical strategy. She serves as an advisor to multiple biotechnology companies. Kristen's scientific background is in aging biology, genetics, and bioinformatics. She received her PhD in Medical Biophysics from the University of Toronto, followed by postdoctoral training at Stanford University where she was a fellow of the Ellison Medical Foundation / American Federation for Aging Research.
Jim O'Neill is a seasoned healthcare executive and science policy expert who was recently nominated to serve as the Director of the National Science Foundation (NSF). His public service is marked by his tenure as the U.S. Deputy Secretary of Health and Human Services (HHS) from June 2025 to February 2026, where he functioned as the department's chief operating officer. During this period, he also concurrently served as the Acting Director of the Centers for Disease Control and Prevention (CDC), stepping into the role in August 2025 to lead the agency through a significant period of administrative restructuring and policy shifts. O'Neill's work at HHS was characterized by a focus on operational efficiency and a libertarian-leaning approach to federal regulation, particularly regarding the acceleration of medical innovation. Prior to his 2025 appointment, O'Neill established a prominent career at the intersection of biotechnology and venture capital. He served as the CEO of the SENS Research Foundation, a medical organization dedicated to regenerative medicine and anti-aging research, and was a managing director at Mithril Capital Management, an investment firm co-founded by Peter Thiel. His deep roots in the 'Thiel ecosystem' also include serving as the CEO of the Thiel Foundation and co-founding the Thiel Fellowship, which supports young entrepreneurs in science and technology. O'Neill first served at HHS during the George W. Bush administration in several senior roles, including Principal Associate Deputy Secretary. A graduate of Yale University with a master's degree from the University of Chicago, he is a long-standing advocate for modernizing the FDA and utilizing emerging technologies to extend human healthspan.
Karl Pfleger is a prominent angel investor in the longevity sector, known for his involvement with Repair Biotechnologies, a company focused on using gene therapy to combat age-related diseases. Beyond his investment and active participation in conferences, Pfleger also manages Aging Biotech Info, which started as a directory of longevity industry companies and has since expanded to include a wide range of resources, such as information on conferences, books, blogs, interventions, diagnostics, and more. The website describes itself as 'Structured info about aging and longevity', and has the declared mission statement, 'Everything important in the field (outside of academia), organised.' Before diving into the longevity space, Pfleger worked at Google from 2002 to 2013 as a research scientist and data analyst, applying AI and machine learning at scale. He holds a BSE in Computer Science from Princeton and a PhD in Computer Science and AI from Stanford. An avid supporter of the Buck Institute and SENS Foundation, Pfleger has also invested in over 15 aging-related startups. He is the founder of AgingBiotech.info, a free public platform designed to track the commercialisation progress of the aging biotech industry and provide related insights.
Jay Olshansky received his Ph.D. in Sociology at the University of Chicago in 1984. He is a Professor in the School of Public Health at the University of Illinois at Chicago, Research Associate at the Center on Aging at the University of Chicago, former Chief Scientist at Lapetus Solutions, Inc. — a company that he co-founded, and former Chief Scientist at Wealthspan Financial Partners, LLC. The focus of his research is on estimates of the upper limits to human longevity, the health and public policy implications associated with individual and population aging, forecasts of the size, survival, and age structure of the population, pursuit of the scientific means to slow aging in people (The Longevity Dividend), and global implications of the re-emergence of infectious and parasitic diseases. During the last 40 years, Dr. Olshansky has been working with colleagues in the biological sciences to develop the modern 'biodemographic paradigm' of mortality — an effort to understand the biological nature of the survival and dying out processes of living organisms. Dr. Olshansky is the first author of The Quest for Immortality: Science at the Frontiers of Aging (Norton, 2001); A Measured Breath of Life (2013); The Rise of Generians (2020); Pursuing Wealthspan (2020); co-editor of Aging: The Longevity Dividend (Cold Spring Harbor Laboratory Press, 2015); and co-editor of Aging: Geroscience as the New Public Health Frontier (Cold Spring Harbor Laboratory Press, 2024). Dr. Olshansky's recent work is focused on linking the scientific study of aging with investments in longevity and mortality related products. Dr. Olshansky is a former Board member, American Federation of Aging Research (AFAR), U.S. Preventive Medicine, and he served on the Board of Scientific Advisors at PepsiCo. Dr. Olshansky has been honored with the Donald P. Kent Award from the Gerontological Society of America, the Irving S. Wright Award from the American Federation for Aging Research, he was named a Next Avenue Influencer in Aging; he received the Alvar Svanborg Award, the Glenn Award from the Glenn Foundation for Medical Research, the Kathy N. Johnson Achievement Award from Home Care Assistance, he was a Senior Fulbright Scholar in France, and was recognized by the Mayo Clinic with the George Randolph and Patricia Scott Visiting Professorship on the Physiology of Aging. In 2022, Dr. Olshansky testified before the U.S. House Committee on Science, Space, and Technology on the topic of aging and Geroscience and how advances in aging biology are about to transform what it means to grow old.
Dr. Alexander Fleming is Founder and Executive Chairman of Kinexum and President and Co-Founder of Kitalys Institute. Dr. Fleming received his M.D. and internal medicine training from Emory, and did fellowships in endocrinology at Vanderbilt and in metabolism at the National Institutes of Health, where he was a senior fellow. At the US Food and Drug Administration from 1986–98, Dr. Fleming was responsible for therapies related to nutrition; disorders of growth, development, and reproduction; diabetes and its complications; and other metabolic and endocrine diseases. He led reviews of landmark approvals including metformin and the first statin, insulin analog, PPAR-agonist, and growth hormone for non-GH deficiency indications. He helped shape FDA policies and practices related to therapeutic review and regulatory communication. He was a major contributor to FDA's Good Review Practice (GRP) initiative and led the committee responsible for education and training at FDA's Center for Drug Evaluation and Research (CDER). He conceived of and directed the first FDA pilot project to utilize the internet for regulatory communication. Dr. Fleming has authored many scientific articles, books, and book chapters. He has been a member of many corporate and advisory boards to academic and commercial institutions and professional societies. He serves on the joint technology working groups of the European Association for the Study of Diabetes and American Diabetes Association. Dr. Fleming coined the term 'metabesity,' which refers to the constellation of cancer, heart and neurologic diseases, diabetes, and the aging process itself, all which share targetable root causes. He co-founded the Targeting Metabesity Conference, since renamed the Targeting Healthy Longevity Conference (THL), in 2017. Since the inaugural meeting in London, over 200 THL sessions have been produced to date. In 2020, Dr. Fleming started the not-for-profit Kitalys Institute to produce THL and other meetings and support initiatives involving FDA and the US Congress.
Lowell M. Zeta, J.D., is the Deputy Commissioner for Strategic Initiatives at the U.S. Food and Drug Administration and serves as Special Counsel for FDA in the Office of the Chief Counsel (OCC), which is the Food and Drug Division of the U.S. Department of Health and Human Services' (HHS) Office of the General Counsel. In this dual role, Mr. Zeta provides legal and strategic counsel to the FDA Commissioner and Agency leadership to advance strategic regulatory initiatives, drive cross-agency innovation, and strengthen oversight across all FDA-related product areas including drugs, biologics, food, medical devices, cosmetics, veterinary products, and tobacco products. He serves as the point-person ensuring that strategic initiatives and priorities, at all levels of the organization, are authorized under the Federal Food, Drug, and Cosmetic Act (FDCA) and other applicable laws and regulations, and are in line with the FDA Commissioner's priorities and the broader goals of HHS and the Administration. Mr. Zeta is responsible for collaborating with the FDA Commissioner to identify opportunities to improve regulatory programs, to develop innovative strategies to emerging and ongoing issues, and to implement new programs and solutions to achieve the FDA's mission objectives. He works closely with FDA leadership and provides executive oversight for operations and regulatory process improvements. His responsibilities include providing analyses and recommendations on innovative regulatory initiatives and programs, ensuring the alignment of the key functions of strategy planning, and driving change and overseeing change management during implementation to maximize efficiency and public health benefit. As Special Counsel for FDA, Mr. Zeta provides legal counsel and strategic counsel on high-priority regulatory and administrative actions and cross-cutting legal issues involving emerging technologies such as artificial intelligence, domestic manufacturing and foreign inspections, and risk management for regulations, guidance, and policy development, which often involves complex legal analyses of intricate statutory provisions. He works closely with OCC litigators and counselors to advise FDA officials on strategy planning and risk mitigation approaches, new and pending regulations and draft legislation, and complex compliance and enforcement matters to advance FDA's mission of promoting and protecting the public health. Mr. Zeta was previously with the FDA (2020-2021), serving as a Senior Advisor to the Commissioner, and provided leadership on key public health initiatives, including the Pandemic Recovery and Preparedness Plan (PREPP) initiative to strengthen the FDA's response to public health emergencies. Prior to his return, Mr. Zeta was a senior partner at a global law firm in Washington, D.C., focusing on regulatory and commercial strategies, enforcement and administrative matters, compliance and investigations involving the pharmaceutical and biotech industries. In addition, he has extensive experience, and is a frequent speaker and published writer on FDA and healthcare priorities. Mr. Zeta previously served as a Food and Drug Law Journal advisory board member where he was responsible for peer-review of publications in the Food and Drug Law Journal, covering scholarly work on legislation, regulations, court decisions, and public policies affecting FDA regulated industries. Mr. Zeta completed his undergraduate studies at the University of Iowa and earned his juris doctor and postgraduate degree in law and health policy from Creighton University and Georgetown University, respectively.
Dr. Eric Morgen is co-founder and Chief Operating Officer at BioAge. He has extensive experience in drug target and biomarker discovery using high-dimensional datasets from human cohorts, with >20 published papers spanning these areas in aging and diagnostic medicine. Eric was previously an assistant professor at the University of Toronto. He completed residency, clinical fellowship, and a research fellowship in computational biology and molecular epidemiology at Mount Sinai Hospital and the University Health Network in Toronto, where he was also a Canadian Institutes of Health Research (CIHR) research fellow. Eric received his MD, MPH, and bachelors in artificial intelligence from the University of Toronto, where he held a Canada Graduate Scholarship from the CIHR. He is a licentiate of the Medical Council of Canada, a fellow of the Royal College of Physicians and Surgeons of Canada, and holds a specialty designation in pathology.
Sonia Arrison is an entrepreneur, investor, and best-selling author. She is founder of 100 Plus Capital, Chair of the Alliance for Longevity Initiatives, Venture Partner at Portfolia, and advisor to Felicis Ventures, focusing on the convergence of biology and technology. Previously, she was co-founder of Unsugarcoat Media (acquired by Medium), board member at the Thiel Foundation, an associate founder of Singularity University, a director and Senior Fellow in Tech Studies at the Pacific Research Institute, board member at Woodland School, and a weekly columnist at TechNewsWorld. Sonia has always been interested in exponentially growing technologies and their impact on society. Her most recent book, 100 Plus: How the Coming Age of Longevity Will Change Everything, From Careers and Relationships to Family and Faith, addresses the social, economic, and cultural impacts of radical human longevity. It gained national best-seller status and still keeps Sonia busy speaking all over the world. Sonia is currently a Board Member at the Foresight Institute and The Alliance for Longevity Initiatives. She is a Senior Fellow at the Fraser Institute in Vancouver, British Columbia, author of two previous books (Western Visions and Digital Dialog) and author of many papers on technology and public policy.
Gloria Elliot, PhD is a Program Manager in the Scalable Solutions office at ARPA-H.
Sarah Ocañas, PhD, is an assistant professor in the Genes and Human Disease Research Program at the Oklahoma Medical Research Foundation (OMRF) and Adjunct Assistant Professor in the Departments of Physiology and Neuroscience at the University of Oklahoma Health Sciences Center (OUHSC). Ocañas was awarded the 2022 NIH Director’s Early Independence Award and recently started her own research group. The Ocañas lab is working to uncover the genomic and hormonal drivers of sex differences in the aging brain and with Alzheimer’s disease (AD), with the ultimate goal of developing sex-informed therapeutics for AD. Ocañas earned her doctorate at the OUHSC for her NRSA-F31 dissertation project, “Epigenetic regulation of sexually divergent neuroinflammation with brain aging and AD.” Before her doctorate, Ocañas completed her bachelor's of science in Biology and Mathematics at the State University of New York Geneseo and her master's of science in Mathematics at the University of Texas at Brownsville, focusing on computational molecular biology.
Guy Leitersdorf is the Founder and CEO of Longevity AI, a Tel Aviv-based digital health company revolutionizing preventive healthcare through artificial intelligence. He is also a Lecturer in Medical Entrepreneurship at the Tel Aviv University MBA Program and a Strategic Advisor for Xone Precision Medicine.
With over 10 years of technological leadership and expertise in AI-driven behavioral technology, Guy is pioneering the integration of advanced algorithms, real-time biomarker analysis, and behavioral science to transform how healthcare providers deliver proactive, personalized longevity care.
Gayland serves as a strategic legal partner to providers and stakeholders across the health care spectrum, including hospitals, ambulatory surgery centers, physician practices, clinical laboratories, telehealth providers, digital therapeutics companies, and data-driven and AI-enabled health technology firms. He is particularly known for advising clients operating at the intersection of regulated health care delivery, consumer health and wellness, and technological innovation, where traditional health care laws increasingly overlap with consumer protection, data privacy, and advertising regimes.
Tom Zuber is the founder and Managing Partner of Zuber Lawler LLP, a national law firm representing clients worldwide in M&A, finance, IPOs, intellectual property, regulatory work, and litigation. Since founding the firm in 2003, he has grown it from a two-person practice into a top-tier firm with over 50 attorneys across offices in Los Angeles, New York, Chicago, Phoenix, and Silicon Valley. Under his leadership, Zuber Lawler has counseled a wide range of bioscience companies, from Fortune 500 pharmaceutical and biotech leaders to pioneering start-ups developing disruptive longevity solutions. The firm merges sophisticated legal acumen with deep scientific and technical fluency—many attorneys hold degrees in biosciences, engineering, and related fields—enabling representation in genomics, regenerative medicine, cellular therapies, and AI-driven drug discovery.
Pete O’Heeron is one of the most preeminent biopharma inventors of his generation, with over 350+ patents issued and pending in the areas of biologics, cell therapy and medical devices. Mr. O’Heeron is Chief Executive Officer of FibroBiologics and a seasoned leader in his field comprising over 25 years of experience in medical technology and biotech development. As CEO, he has positioned FibroBiologics to become a global leader in fibroblast-based cell therapies with the development and commercialization of therapies that can cure and treat patients suffering from chronic diseases. He brings together multi-disciplinary teams and resources necessary to commercialize unique technologies and currently holds 350+ Patents Issued/Pending.
Prior to founding FibroBiologics/FibroGenesis, LLC, he founded an operational investment group, Advanced Medical Technologies, LLC, that identified early-stage opportunities in the medical field with strong intellectual property potential. He also founded NeoSurg Technologies that developed the T2000 Minimally Invasive Access System. The sale of NeoSurg Technologies to Cooper Surgical occurred in 2006.
He brings decades of executive-level experience at Christus Health Care Corporation and strategic advisory to healthcare companies in the areas of biologics, advanced surgical instrumentation, and telemedicine to his company along with an academic foundation rooted in healthcare administration. He received his Bachelor’s Degree in Healthcare Administration at Texas State University, his Masters in Healthcare Administration from the University of Houston Clear Lake, and his Executive Management Certification in Mergers and Acquisition from University of Chicago.
Roschon Johnson is an American professional football running back for the Chicago Bears of the National Football League (NFL). He played college football for the Texas Longhorns and was selected by the Bears in the fourth round of the 2023 NFL draft.
Dr. Ramunas switched from electrical engineering to biochemistry when he read a 1998 Science paper on telomeres, the tips of DNA that shorten with each cell division, until they stop stem cells from dividing, halting regeneration and driving aging and disease. This simple yet central mechanism of aging inspired him to pursue technologies to reverse such mechanisms to prevent aging and disease. To that end he has co-invented technologies spanning stem cell bioengineering, drug delivery pumps and vehicles, and RNA-based protein replacement. He and his grad school labmate Glenn Markov and their supervisor Helen Blau founded Rejuvenation Technologies, licensing tech they invented at Stanford, and have achieved spatiotemporal control of telomere extension in vivo, extending telomeres by over 5 years with one dose and demonstrating profound therapeutic impact in multiple preclinical models of age-related diseases. Rejuvenation is currently raising its Series A funding round for clinical trials in longevity, immuno-oncology, hematology, and pulmonology.
Todd White is the Managing Director of Thalion Initiative. He has an extensive background in all aspects of technology company startup, operations and commercialization. Todd started his career in telecommunications with a background in electrical engineering and computer science, and progressed through senior R&D engineering roles leading into C-level management. After 25 years in the telecommunications industry, Todd sought a new challenge and became interested in the biology of aging and the state of biomedical innovation. Since 2018, he has worked to help fund early stage aging research as an angel investor, advisor, and operations lead as part of the decentralized science (“DeSci”) community.
Dr. Carrie Graham is a Research Professor and Director of the Medicare Policy Initiative at Georgetown University’s Center on Health Insurance Reform (CHIR), where she leads policy analysis, research, and technical assistance on Medicare Advantage and original Medicare.
She previously served as Director of Aging and Disability Policy at the Center for Health Care Strategies and holds an Adjunct Professor appointment at the University of California, San Francisco, Institute for Health and Aging.
Her work spans aging research, health policy, and evaluation research. She has helped evaluate California’s Dual Financial Alignment Initiative, served as a Health and Aging Policy Fellow in the U.S. House of Representatives, and supported state aging plans in California and more than 20 other states.
Dr. Graham holds a doctorate in medical sociology from UCSF, a master’s degree in gerontological studies from the Scripps Gerontology Center at Miami University, and a bachelor’s degree from the University of California, San Diego in sociology and African studies.
An internationally known expert on nutritional influences that affect trajectories of health and disability in older adults, including vitamins, protein, energy balance, exercise and obesity, I have more than 450 peer-reviewed publications, lead Wake Forest Baptist’s NIA-funded Claude D Pepper Older Americans Independence Center (OAIC), and co-direct the Sticht Center for Healthy Aging and Alzheimer’s Prevention. I have participated in some of the most important aging-related multicenter studies in the past 20 years, including the Health ABC study and the Life Style Interventions and Independence for Elders (LIFE) Trial, and I am the past editor-in-chief of the Journals of Gerontology: Medical Sciences.
I lead the Research Centers Collaborative Network (RCCN) with the American Federation for Aging Research. The RCCN’s goal is to build research collaborations among the six NIA Center’s programs through workshops, pilot awards, and educational activities. Through my service on the National Advisory Council on Aging, I help shape national research priorities for aging research. My recent work focuses on translating the new discoveries in the biology aging to prevent age-related diseases and extend health span in older adults.
Dr. Susanna Rosi is a Principal Investigator at the Altos Labs Bay Area Institute of Science.
Susanna is a Principal Investigator at the Altos Labs Bay Area Institute of Science. Prior to joining Altos, Susanna was the Lewis and Ruth Cozen Chair II, Professor in the Departments of Physical Therapy Rehabilitation Science and Neurological Surgery at UCSF. Susanna studies the mechanisms responsible for the cognitive dysfunctions observed after traumatic brain injury, therapeutic brain irradiation and galactic cosmic ray exposure. Her work provided the mechanistic evidence for the role of microglia in the development of cognitive deficits after brain injury based on sex. She was the first to demonstrate that modulation of the Integrated Stress Response rescues cognitive deficits after brain trauma; rejuvenates old mice by alleviating memory deficits and restoring neuronal and immune dysfunction. Susanna has been the recipient of several NCI, NIA, NINDS awards and she is a NASA investigator. Most recently she received the 2021 J.W. Osborne Award.
Tim Peterson, Ph.D. is CEO and Founder of BIOIO and of Healthspan Technologies. He is also a Core Member of the Longevity Working Group at VitaDAO.
BIOIO was founded by Tim in 2017 with the goal to better understand how drugs work. In particular, they leverage their learnings on how widely used medicines, such as rapamycin, metformin, bisphosphonates, and antidepressants, work. This led them to define a gold standard for drug Mechanism of Action (MoA) elucidation, leading to their genetics-based MOAT platform.
Petr Sramek is Managing Partner of Longevitytech.fund and co-founder of LongevityForum.eu. He is a serial entrepreneur in deep tech for more than 30 years. Petr is building science, funding and business infrastructure to support faster adoption of health-span improving technologies. Petr was Entrepreneur in Residence at Singularity University, co-founder of the Platform on Artificial Intelligence at the Confederation of Industry, AI Startup Incubator founder and a Senator for the Czech Republic in the World Business Angels Investment Forum (WBAF). Petr is also the founder of the AI Awards project. Petr has been featured in the group of 28 AI leaders in the flagship World Intellectual Property Organization study.
Dr. Xiaoxi (Sofie) Wei is an award-winning American entrepreneur and inventor in the area of biomimetic nanoscience and biopreservation in Regenerative Medicine. Being persistent in her life vision to enable “on-demand organs” from a very young age, she pursued her scientific endeavor in biomimetic Chemistry at SUNY Buffalo, earning her doctorate.
Inheriting the entrepreneurial spirit from her family, she successfully managed $8M in engineering projects while completing her Ph.D. Then she founded X-Therma in the San Francisco Bay Area in Oct 2014 to bring lab innovation to patients.
Dr. Wei is the inventor of X-Therma’s core technologies based on biomimetic hyper-effective ice prevention materials and devices, resulting in 17 issued global patents. She has served as principal investigator or co-PI of 12 national and international innovation research grants with accumulated value exceeding $14M USD from DoD, NSF, NIH, CIRM, EU etc. She has led the X-Therma research endeavors at The Molecular Foundry, Lawrence Berkeley National Laboratory 2015-2024. She serves as a healthcare advisor for the UC Regents working group on innovation transfer and entrepreneurship, is a scientific advisor for Life Extension Foundation, and was the Vice Chair of the Younger Chemists Committee of the American Chemical Society (ACS), and Cal ACS Executive Committee Member. She is currently a distinguished member of the RULEBREAKER Society, in Germany.
Moshe Levi, MD, is a professor in the Department of Biochemistry and Molecular & Cellular Biology at Georgetown University Medical Center.
Levi completed undergraduate training in chemical engineering at Northwestern University and received an MS in chemical engineering at Stanford University. He earned his MD from Albert Einstein College of Medicine and completed his internal medicine internship and residency at Cornell University and Memorial Sloan Kettering Hospital. He completed a nephrology clinical and research fellowship at the University of Colorado Health Sciences Center.
Funded by numerous NIH grants including three R01s in progress or concluding this year, Levi’s research involves renal and cardiovascular complications of obesity, diabetes and aging; regulation of mineral metabolism; and applying new label free techniques for imaging lipids, inflammation, oxidative stress, metabolism, and fibrosis. He has co-author 200 manuscripts and nearly 40 book chapters, and has mentored more than 20 MD or PhD research trainees.
Prior to joining Georgetown, from 2002 to 2017, Levi was professor of medicine, physiology and biophysics, and bioengineering at the University of Colorado Health Sciences Center, where from 2005 to 2011 he served as Vice Chair of Research for the Department of Medicine with over 400 faculty members. He also served on the executive committee of the NIH CCTSI Microscopy Technology Core Lab and the Clinical and Translational Imaging Research Center, and as a member of the Center for Fibrosis Research and Translation. Earlier in his career, Levi practiced medicine at the Department of Veterans Affairs Medical Center in Dallas where he was chief of the nephrology section, and at University of Texas Southwestern Medical Center from 1984 to 2002 where he was professor of internal medicine.
Levi has served on numerous study sections and associated grant review committees.
In 2013, he was appointed a member of the Board of Scientific Counselors for the NIH’s National Institute of Diabetes and Digestive and Kidney Diseases and recently concluded his service as its chair.
Levi continues to serve as an NIH National Advisory Committee member for the Laboratory for Fluorescence Dynamics at the University of California Irvine, the O’Brien Center in Kidney Research at UT Southwestern Medical School and for the Beckman Laser Institute and UC Irvine.
Levi is a fellow of the American Heart Association, the American Society of Nephrology, and the American Physiological Society, and is a member of numerous professional associations where he has served in committees and leadership roles. Memberships include the American Physiological Society, the American Society of Nephrology, National Kidney Foundation, International Society of Nephrology, American Heart Association, American Diabetes Association, Juvenile Diabetes Research Foundation, the American Association for the Advancement of Science, Biophysical Society, American Society for Biochemistry and Molecular Biology, American Society for Cell Biology, and the American Association for the Study of Liver Disease.
He serves on the editorial boards of the Journal of Biological Chemistry, Diabetes, and American Journal of Physiology: Renal Physiology.
Levi is a married to a physician and is the father of two young adult children
Pamela A. Saunders, PhD (she, hers) is a professor in the departments of neurology and psychiatry. In 2024, she was named Co-Director of the Georgetown Center for Health Aging. Her research focuses on communicative coping behaviors, language, aging, doctor/patient communication, empathy, narrative and reflective writing, and standardized patient education. She has spent the last 30 years conducting research and teaching. Her research portfolio includes funding from the Alzheimer’s Association, the National Institute on Aging, the Hartford Foundation, and the U.S. Food and Drug Administration. She has served in several leadership roles, including director of the geriatrics clerkship and longitudinal thread in Aging & Geriatrics. She co-founded the geriatrics curriculum in 2003 at Georgetown’s School of Medicine with funding from the Hartford Foundation. Dr. Saunders is the founding director of the Aging & Health Program, which offers certificates and a master of science in Aging & Health (aging.georgetown.edu). Courses include reflective writing, Mind-Body Medicine skills to medical and graduate students, as well as courses in gerontology, reflective writing, research methods, and ageism. She lives in Falls Church, VA, with her husband, twin boys, and dog, Fancy.
A veteran legislator, Congressman Paul Tonko has represented New York’s 20th District since January 2009. With 17 years of experience in Congress, he is a high-ranking member of the House Committee on Energy and Commerce, serving as the Ranking Member for the Subcommittee on Environment. He also holds assignments on the Subcommittees on Energy and on Oversight & Investigations, as well as the House Committee on the Budget. His work is deeply informed by his background in engineering, specifically focusing on clean energy and environmental protection.
Dr. O’Connor was awarded his master’s degree in neuroscience from Northwestern Medical in 1999 and his Ph.D. in Biochemistry from Baylor College of Medicine in 2005. His postdoctoral research includes work at UC Berkeley on muscle stem cells and aging. He is the former VP of Research at SENS Research Foundation where he oversaw a broad swath of research projects spanning many aspects of rejuvenation biotechnology from which he authored many papers and patents.
Dr. Morgan Levine is a Vice President of Computation at Altos Labs and formerly a Principal Investigator at the San Diego Institute of Science.
Prior to joining Altos, Morgan was a ladder rank professor at Yale University School of Medicine. She is considered a leader in the biology of aging, most famous for generating cutting-edge methods for quantifying the system dysregulation that occurs over an organism’s lifetime. Her work relies on interdisciplinary approaches, integrating theories and techniques from computational and cellular biology to track trajectories aging cells and organisms take over time. Morgan’s vision is to develop multi-scale computational models that translate how dynamic molecular states of cells lead to manifestations of health and disease at the tissue, organ-system, or organismal level. She has received numerous awards for her work, including the Vincent Cristofalo Rising Star Award in Aging Research in 2021 and the Nathan Shock New Investigator Award in 2020.
Matt Peloquin is a translational research scientist and biotech executive with over a decade of experience in drug discovery and development. He currently serves as Vice President of Research at Loyal Animal Health, a biotechnology company developing therapeutics for lifespan and healthspan extension in dogs. Since joining Loyal in 2021, he has contributed to the research and regulatory strategies that resulted in the first and second FDA CVM efficacy approvals for lifespan extension in dogs. Prior to Loyal, Matt led multiple preclinical drug discovery programs in Pfizer’s Internal Medicine Research Unit, which focused on targeting various metabolic diseases, cancer cachexia and sarcopenia. Matt’s work has been published in high impact journals, such as Nature Communications, Aging Cell and the Journal of Cachexia, Sarcopenia and Muscle.
Louise Hecker, PhD is an Associate Professor at Baylor College of Medicine and the Founder and Chief Scientific Officer at Fibronox with over 15 years of experience in regenerative biology, fibrosis research, and age-related disease therapeutics. She is a world-leading expert on Nox4 and Nrf2, having made numerous seminal discoveries in understanding how oxidative stress contributes to tissue fibrosis and aging.
Her groundbreaking research has revolutionized the understanding of fibrotic diseases and recently expanded into psychedelic medicine, where her team discovered that psilocybin extends cellular lifespan by up to 57% and improves survival in aged mice. As an academic entrepreneur, she has founded five companies and secured approximately $15 million in research funding as Principal Investigator while holding around 20 patent applications. Read Psilocybin treatment extends cellular lifespan and improves survival of aged mice.
Louise currently serves as an Associate Professor in the Department of Medicine at Baylor College of Medicine since December 2024 and maintains her position as Founder and Chief Scientific Officer of Fibronox, a pharmaceutical startup she established in November 2017 to develop novel Nox4 inhibitors for treating fibrotic diseases.
Dr. Matt Kaeberlein is the Chief Executive Officer at Optispan, Inc., Affiliate Professor of Oral Health Sciences at the University of Washington, and Co-Director of the Dog Aging Project. Dr. Kaeberlein’s research interests are focused on understanding biological mechanisms of aging in order to facilitate translational interventions that promote healthspan and improve quality of life for people and companion animals. He is a Fellow of the American Association for the Advancement of Science (AAAS), the American Aging Association (AGE), and the Gerontological Society of America (GSA). Dr. Kaeberlein has published more than 250 scientific papers in the field of aging biology and has received several prestigious awards including young investigator awards from the Ellison Medical Foundation and the Alzheimer’s Association, the Vincent Cristofalo Rising Star in Aging Research Award, the Murdock Trust Award, the NIA Nathan W. Shock Award, and the Robert W. Kleemeier Award for outstanding research in the field of gerontology. Dr. Kaeberlein is the founding Director of the University of Washington Healthy Aging and Longevity Research Institute, former Director of the NIH Nathan Shock Center of Excellence in the Basic Biology of Aging and the Biological Mechanisms of Healthy Aging Training Program at the University of Washington, and former CEO and Chair of the American Aging Association.
Dr. Barnes’ principal professional interest is to develop therapies to protect valuable human lives against aging and age-related disease. He earned his BS in Biology from SUNY Oswego and his PhD in Neuroscience from Weill Cornell Medicine, after which he was a competitive intelligence consultant in the biotech space with focus on multiple types of chronic diseases including in ophthalmology. He founded Lento Bio at idea-stage in 2022 with the goal of developing novel treatments for chronic aging disorders of the lens, having in the 3 years since developed and patented Lento Bio’s current lead presbyopia asset.
Dr. Laura Niedernhofer is the Director of the Masonic Institute on the Biology of Aging and Metabolism (MIBAM) and Medical Discovery Team on the Biology of Aging. She is also a Professor in the Department of Biochemistry, Molecular Biology and Biophysics at UMN. Dr. Niedernhofer’s expertise is in DNA damage and repair, genome instability disorders, cellular senescence and aging. Her research program is centered on studying fundamental mechanisms of aging and developing therapeutics to target them. Her research program implements a murine model of a human progeroid syndrome caused by a defect in DNA repair. She contributed to the discovery of a new class of drugs called senolytics. Laura has served on study section for NCI, NIEHS and NIA. She has been awarded for research in aging, cancer and environmental health science.
Historically, the aging field was divided as to whether lifespan was dictated by genetics or environmental factors. We demonstrated that removing DNA repair defenses causes accelerated aging. This supports the conclusion that DNA damage can drive aging, if not repaired. Traditionally, biomedical research has focused on identifying molecular targets for treating a single disease. However, 75% of individuals over the age of 65 have 2 or more chronic degenerative diseases. My group has been at the forefront of seeking therapeutic interventions to treat aging itself and thereby prevent or attenuate multiple age-related diseases simultaneously. There is clearly an attrition of stem cell numbers and function with aging. But what was not clear is if this is a cause or consequence of aging. We demonstrated that the former is true, based on the finding that treating progeroid mice with muscle-derived stem cells from young mice was sufficient to slow down aging. This clearly shows that stem cell dysfunction contributes to aging and provides a scientific basis for treating age-related degenerative diseases with stem cell therapy.
There are over a thousand oncology studies in which the expression of ERCC1 repair protein is measured in tumors to determine if there is a correlation with response to therapy or patient outcomes. We discovered novel roles for ERCC1-XPF in the repair of DNA interstrand crosslinks and double-strand breaks, revealing important roles for the enzyme in coping with platinum-based and radiation therapy, respectively. In addition, we discovered that the antibody used to detect ERCC1 in tumoral tissue was non-specific. We discovered that the protein to which the antibody was cross-reacting was rate-limiting for cell growth and regulated by RAS.
Dr. Gladden the visionary founder of Gladden Longevity and Advanced Performance Center, initially practiced as an interventional cardiologist before pivoting his focus from late-stage interventions to preventing heart issues and unlocking ageless potential. Seamlessly blending science, wisdom, and innovation, he’s unraveling the secrets of Living Young for a Lifetime™, harmonizing Life Energy, Longevity, Health, and Human Performance. Beyond pioneering research, Dr. Gladden enjoys adventures in surfing, biking, hiking, snowboarding, and guitar playing. Amid these pursuits, he treasures moments with loved ones. Jeff’s dedication to inspiring vitality echoes through his work, driven by an unwavering commitment to guiding individuals toward embracing their potential and creating an enduring legacy in the world.
James C. Greenwood is a Senior Policy Advisor at the DLA Piper law firm, chairing its Life Science Health Policy and Regulatory group. He is the President Emeritus of the Biotechnology Industry Organization (BIO) in Washington, D.C., where he served as President and CEO from 2005-2020.
Mr. Greenwood represented Pennsylvania’s Eighth District in the U.S. House of Representatives from January 1993 through January 2005. A senior member of the Energy and Commerce Committee, he was widely viewed as a leader on health care and the environment. From 2001 to 2004, Mr. Greenwood served as Chairman of the Energy and Commerce Committee Subcommittee on Oversight and Investigation with oversight authority over issues in the full Committee’s vast jurisdiction. Prior to his election to Congress, Mr. Greenwood served six years in the Pennsylvania General Assembly (1981-86) and six years in the Pennsylvania Senate (1987-1992).
Mr. Greenwood graduated from Dickinson College in 1973 with a BA in Sociology. From 1977 until 1980, he worked as a caseworker with abused and neglected children at the Bucks County Children and Youth Social Service Agency. Mr. Greenwood is married with three children and resides in Upper Makefield Township, Pennsylvania.
At BIO, Mr. Greenwood led the organization through a period of major policy engagement on biotechnology, biomedical innovation, and patient access to new therapies. As President and CEO, he represented the industry before policymakers, helped advance legislative and regulatory priorities, and worked to strengthen the visibility of life sciences as a driver of health and economic growth. In his role as President Emeritus, he continues to be associated with BIO’s mission and its long-standing efforts to support innovation, research, and the responsible development of new medical technologies.
Joe Betts-LaCroix, CEO of Retro Biosciences, is dedicated to extending healthy human lifespan by ten years. A scientist-turned-entrepreneur, he began his career at Harvard, MIT, and Caltech, where he co-discovered key factors governing electron-tunneling rates in proteins, with his research published leading journals, accumulating over 1,500 citations.
Joe has co-founded three venture-backed startups. His first, OQO, created the world’s smallest Windows computer (Guinness World Record, 2006) and was later acquired by Google. His second, Vium, leveraged automation and AI to accelerate in vivo research and was acquired by Recursion Pharma. He also spent several years as a part-time partner at Y Combinator, mentoring and investing in biotech startups.
Now, as CEO of Retro Biosciences, he is bringing urgency and focus to the challenge of aging, leading a team exploring numerous novel approaches to longevity therapeutics. By accelerating discovery and translation, Retro aims to make meaningful gains in extending healthspan within our lifetime.
As CEO of Sinaptica Therapeutics, Ken is leading the team to advance the company’s personalized precision neuromodulation therapy for Alzheimer’s.
Prior to Sinaptica, Ken has 20+ years leading and growing new business ventures on both the ‘Buy Side’ and the ‘Build Side.’
He started his career in management consulting at Charles River Associates, then jumped to industry at CSL, then Baxter BioScience (now Takeda), and Boston Scientific, with leadership roles in marketing, strategy, and corporate development. At Boston Scientific’s nearly $1B Neuromodulation division, he was the global commercial lead for the highly successful Cosman RF ablation business he helped acquire.
He also built the division’s Strategy function, providing leadership in areas including strategic planning, BD assessment, R&D portfolio management, digital strategy, and investments in next-gen platforms & new indications. In 2019 he joined EBT Medical, a venture-backed, clinical-stage startup developing a disruptive neuromodulation device for overactive bladder, where he oversaw all commercial aspects.
Francisco LePort is co-founder and CEO of Gordian Biotechnology. Gordian Biotechnology has developed in vivo perturb seq technology that simultaneously measures the safety and efficacy of thousands of arbitrary genetic perturbations, directly in individual living animal models of any given age-related disease. Having raised $60M to date, Gordian is developing first-in-class therapeutics for obesity, heart failure, kidney disease, and osteoarthritis. Prior to Gordian, Francisco graduated with a BS in Physics from UC Irvine at the age of 17, and a Ph.D in Physics from Stanford University. He has over 15 years of experience applying AI to various industries as a founder, investor, board member, and employee of numerous Bay Area companies.
Dr. Hanadie Yousef is a scientist, entrepreneur, seasoned executive, and global thought leader in AI-driven regenerative medicine and longevity. With over two decades of experience in biomedical research, she is the Co-Founder of Juvena Therapeutics, where she served as CEO, CFO, and Board Chair from 2017 to 2025. Since the company’s incorporation, she pioneered its evolution from a platform-driven concept into a venture-backed, clinical-stage biotechnology leader. Under her leadership, Juvena secured over $105M in venture capital, non-dilutive grants, and partnerships, and developed a proprietary pipeline of tissue-restorative biologics for muscle and metabolic diseases.
Driven by a vision to decode the mechanisms of age-related tissue degeneration, Dr. Yousef leveraged Juvena’s AI-enabled JuvNET platform to map secreted proteins and build a proprietary library of pro-regenerative stem cell-secreted proteins and novel therapeutic candidates. Her leadership led to the successful completion of Phase 1 first-in-human safety studies for the company’s lead asset, JUV-161, targeting Myotonic Dystrophy Type 1 and atrophy-related muscle wasting.
Expanding the boundaries of metabolic health, she advanced a robust preclinical pipeline, including JUV-112, a groundbreaking obesity asset that uniquely enhances lipid metabolism to induce weight loss via an energy-promoting, non-appetite-suppressing mechanism. Validating this platform-first approach, Dr. Yousef secured a prestigious discovery partnership with Eli Lilly to develop novel medicines aimed at enhancing muscle health, body composition, and quality of life for patients with metabolic complications.
Dr. Yousef’s high-impact research has led to multiple issued and pending patents and has been supported by competitive fellowships and grants from the NIH, National Science Foundation, SPARK, and the California Institute for Regenerative Medicine (CIRM).
A recognized authority in the industry, Dr. Yousef was named to the 2025 Mayfield | Divot Industry Leader AI List and designated a World Economic Forum 2024 Technology Pioneer. Her extensive accolades include FierceBiotech’s “Fiercest Women in Life Sciences,” Business Insider’s “30 Leaders Under 40,” Endpoints’ “20(+2) Under 40,” the San Francisco Business Times “Women Who Lead in Life Sciences,” and the Biocom Catalyst Award.
Dr. Yousef is a regularly invited speaker at marquee biotech, AI, and healthcare innovation events. She earned her B.S. summa cum laude from Carnegie Mellon University, her PhD from UC Berkeley as an NSF Fellow, and completed a 5-year postdoctoral fellowship at Stanford School of Medicine as an NIH fellow and SPARK scholar. Her lifelong dedication to biomedical research and entrepreneurship began early, with research positions at Regeneron starting at age 15 and a neuroscience internship at Genentech.
Dr. Jean Hebert joined ARPA-H in August 2024 from the Albert Einstein College of Medicine where he served as a professor of genetics and neuroscience. Hebert is the founder of BE Therapeutics, a company focused on reversing age-related damage to brain tissue. His laboratory research focuses on stem cell transplantation, plasticity, neurodegeneration, and cortical health. In addition to his academic publications, Hebert is also the author of Replacing Aging, a book on regenerative medicine and the types of cellular damage accumulated in aging tissue.
Since childhood, Hebert has been interested in understanding how our bodies work and how to repair them. He has a doctorate in genetics from the University of California San Francisco and completed postdoctoral research at Stanford University studying the development of neurons that make up the neocortex.
Dr. Doug Lucas is a double board–certified orthopedic surgeon and longevity physician dedicated to changing how we understand aging, hormones, and bone health. After years in traditional orthopedic practice, he stepped away from a system that waited for bones to break before taking action and shifted his focus toward prevention, optimization, and healthspan. His work centers on a simple but disruptive idea: bone health is not a geriatric diagnosis—it is a powerful biomarker of longevity, resilience, and overall health.
Dr. Doug is the founder of The OsteoCollective, an international online community where thousands of women and men have successfully reversed osteoporosis and improved bone health with the right education, guidance, and support. He is also Head of Longevity at LifeMD, where he leads both the women’s and men’s health verticals, helping shape modern, proactive care models that integrate hormones, lifestyle, and long-term health optimization across midlife and beyond.
As the host of The Dr. Doug Show: Bones, Hormones & Healthspan and Health 3.0, and the author of two Amazon best-selling books, Dr. Doug is widely recognized for translating complex science into clear, actionable guidance. A sought-after speaker and media guest, he addresses topics ranging from osteoporosis prevention and reversal to hormone optimization, sexual health, metabolic resilience, and strength training for longevity.
Whether on stage, behind the microphone, or on camera, Dr. Doug’s mission is to educate the world that osteoporosis is often preventable, frequently reversible, and best understood not as inevitable decline—but as an opportunity to intervene early, build strength, and age with confidence, vitality, and purpose.
Dylan V. Livingston is the founder and President of the Alliance for Longevity Initiatives (A4LI), the first 501(c)(4) organization in the U.S. devoted exclusively to advancing longevity science through public policy. He launched A4LI in 2022 to combat age-related diseases—including cancer, cardiovascular disease, and Alzheimer’s—by connecting scientific research with legislative action.
Under Livingston’s leadership, A4LI helped establish the bipartisan Longevity Science Caucus and supported state-level Right-to-Try expansion measures SB422 and SB535. He also founded the H-SPAN Summit in Washington, D.C., and led the organization’s first Longevity Science Congressional Briefing in 2024. In 2025, A4LI facilitated more than 70 meetings between advocates and members of Congress, and the 2026 summit will be held in partnership with Georgetown University Medical Center.
Livingston was recognized on Forbes 30 Under 30 for his work in building a national organization focused on longevity policy. Before founding A4LI, he gained experience on political campaigns, including serving as a field organizer for President Joe Biden’s 2020 campaign in Pennsylvania.
Mr. Schulak, Founder and Chairman of EdenRoc Sciences, is an architect, philanthropist, and life sciences investor.
He has served on numerous charitable, academic, and business boards, including the Sanford Burnham Prebys Medical Discovery Institute, the Advisory Board of the New York University Center for Urban Science and currently on the Boards of The University of Michigan Health System Advisory Group (Hospital, Research Center and Medical School), the Harvard Medical School Dean’s Discovery Council, Novim and the Dean’s Council for the University of California Baskin School of Engineering. Mr. Schulak graduated from the Rhode Island School of Design with degrees in both Fine Arts and Architecture.
Eric Morgen Eric is co-founder and Chief Operating Officer at BioAge. He has extensive experience in drug target and biomarker discovery using high-dimensional datasets from human cohorts, with >20 published papers spanning these areas in aging and diagnostic medicine.
Eric was previously an assistant professor at the University of Toronto. He completed residency, clinical fellowship, and a research fellowship in computational biology and molecular epidemiology at Mount Sinai Hospital and the University Health Network in Toronto, where he was also a Canadian Institutes of Health Research (CIHR) research fellow.
Eric received his MD, MPH, and bachelors in artificial intelligence from the University of Toronto, where he held a Canada Graduate Scholarship from the CIHR. He is a licentiate of the Medical Council of Canada, a fellow of the Royal College of Physicians and Surgeons of Canada, and holds a specialty designation in pathology.
Felipe Sierra, Ph.D. is CEO of Geroscience Consulting LLC. He is best known for his contributions to the development of the field of geroscience, a concept he developed while serving as Director of the Division of Aging Biology at the National Institute on Aging (NIA), part of the National Institutes of Health (NIH) in the USA.
Trained as a biochemist in Chile, he obtained a PhD in Biochemistry and Molecular Biology from the University of Florida in 1983 and has since worked in Academia, Industry and Government, in a career that spans multiple geographic areas including South America, USA, Europe (Switzerland and France) and most recently, the Middle East.
Dr. Sierra served as Director of the Division of Aging Biology, NIA/NIH from April 2006 to March 2020, where he developed the concept of Geroscience and created the trans-NIH Geroscience Interest Group (GSIG). After his tenure at NIA/NIH he worked as Director of Geroscience for the Inspire program in Toulouse, France, and most recently, as Chief Scientific Officer at Hevolution Foundation, a non-profit organization headquartered in Riyadh, Saudi Arabia. He retired from that position in March 2025 to start a private consulting venue, Geroscience Consulting LLC.
Dr. Christin Glorioso is a neuroscientist, physician, and serial entrepreneur. She is co-founder and CEO of NeuroAge Therapeutics and Founder and Executive Director of the non-profit, Longevity Global. Previously she was Head of AI of the Stanford Spinout, TeachAids. She has published more than 30 peer reviewed publications and been awarded grants by AFAR, the Glenn Foundation for Medical Research, and the National Institute on Aging. Dr. Glorioso holds an MD and PhD in Neuroscience from the University of Pittsburgh and Carnegie Mellon University’s Medical Scientist Training Program and completed her postdoctoral training at MIT.
Cheryl Sew Hoy founded Tiny Health in 2020 after her first child struggled with eczema, sleep troubles, and food sensitivities. Her experience led her to research the gut microbiome and develop tests focusing on a baby’s first 1,000 days, a crucial period in microbiome development. Cheryl is a serial entrepreneur with extensive expertise in building consumer brands. She holds multiple Engineering degrees from Cornell University.
Christopher Bradley, PhD is the CEO and Cofounder of Matter Bio, a pioneering longevity biotechnology company focused on extending human healthspan through advanced genetic interventions, and an Adjunct Professor in the Department of Technology Management and Innovation at NYU Tandon School of Engineering. He is also the CEO and Founder of Loki Therapeutics, an immuno-oncology company developing next-generation cancer therapeutics.
Chris is a serial entrepreneur with a background in both biology and technology, with over a decade of executive experience founding, funding, and operating complex and innovative healthcare and biotechnology businesses. His current mission is to increase healthy human longevity by addressing two related problems: treating advanced cancer when it already exists and preserving DNA information integrity to prevent disease from emerging.
Dr. Tornatore is the Regional Chief of Neurology for MedStar Health and Chairman and Neurologist-in-Chief in the Department of Neurology at MedStar Georgetown University Hospital. He is also the Executive Director of the Multiple Sclerosis Patient Centered Specialty Practice MedStar Georgetown and Professor and Chairman in the Department of Neurology at Georgetown University Medical Center. Dr. Tornatore received his undergraduate degree in neurobiology from Cornell University and then attended Georgetown University School of Medicine where he received his medical degree. Following a Neurology Residency at Georgetown University Hospital, he was a post-doctoral fellow at the National Institute of Neurologic Disorders and Stroke at the National Institutes of Health. Dr. Tornatore has published extensively in the areas of neuroimmunology, neurovirology and Multiple Sclerosis and is currently involved in over 15 clinical trials for the treatment of Multiple Sclerosis. He has won multiple awards in the areas of medical student teaching, patient care and scholarly research.
Dr. Bill Rebeck is a Professor in the Department of Neuroscience at Georgetown University. He grew up in Cincinnati, OH, and attended Cornell University. After graduating, he worked for three years as a chemist at an agricultural products company and then earned a PhD in Toxicology at Harvard University in 1990. He spent one year on a Fulbright fellowship in Heidelberg, Germany, pursuing research on Alzheimer’s disease in the lab of Konrad Beyreuther. He then began research at Massachusetts General Hospital with Brad Hyman. He moved his lab to Georgetown University in 2003. For over 25 years, Dr. Rebeck, has been interested in genetic risk factors for Alzheimer’s disease, specifically variants of the APOE gene. His lab uses cell culture and mouse models to examine the effects of APOE isoforms on normal brain function prior to the accumulation of Alzheimer’s lesions. He has been very involved in graduate education, serving as assistant director of the MS in Integrative Neuroscience, director of the PhD program in Neuroscience for eight years, and Dean of the Graduate School of Arts and Sciences for 18 months. In 2017, Dr. Rebeck received the Georgetown Presidential Distinguished Scholar-Teacher award.
Dr. Brian Kennedy is internationally recognized for his research in the basic biology of aging and as a visionary committed to translating research discoveries into new ways of detecting, delaying, preventing and treating human aging and associated diseases. He is a Distinguished Professor in Biochemistry and Physiology at the Yong Loo Lin School of Medicine at National University Singapore and serves as Director of (1) the Centre for Healthy Longevity at the National University Health System, (2) the NUS Medicine Healthy Longevity Translational Research Programme, and (3) the Asian Centre for Reproductive Longevity and Equality. Collectively, NUS aging research seeks to demonstrate that longevity interventions can be successfully employed in humans to extend healthspan, the disease-free and highly functional period of life.
From 2010 to 2016, Dr. Kennedy was the President and CEO of the Buck Institute for Research on Aging and he maintained a professorship there through 2020. Dr. Kennedy has an adjunct appointments at the Department of Biochemistry at the University of Washington, where he was a faculty member from 2001 to 2010. In addition, Dr. Kennedy is also actively involved with a number of Biotechnology companies. In addition, Dr. Kennedy serves as a Co-Editor-In-Chief at Aging Cell. Finally, Dr. Kennedy has a track record of interaction in China, where he was a Visiting Professor at the Aging Research Institute at Guangdong Medical College from 2009 to 2014. His Ph.D. was performed in the laboratory of Leonard Guarente at M.I.T., where he published the first paper linking Sirtuins to aging.
Dr. Andrew Brack joined ARPA-H in April 2024 from the University of California San Francisco’s Department of Orthopaedic Surgery. For 16 years, his lab studied the cellular and molecular mechanisms that regulate skeletal muscle repair during aging. He was the co-founder of Arrive Bio, a longevity company that uses machine learning to identify drugs to treat age-related diseases.
Brack received a Ph.D. in molecular biology and biophysics from King’s College London and completed two postdoctoral fellowships, one at King’s College London and the second at Stanford University. Throughout his career Brack has led multidisciplinary teams with the goal of restoring healthy function during aging.
Dr. Alicia Jackson was appointed by President Trump as Director of the Advanced Research Projects Agency for Health (ARPA-H) and sworn in on October 20, 2025. Dr. Jackson reports directly to U.S. Department of Health and Human Services (HHS) Secretary.
Dr. Jackson joins ARPA-H from Evernow, a company she founded and led as CEO, focused on transforming women’s health and longevity during menopause. Previously, she served as a Program Manager and, subsequently, Deputy Director of the Defense Advanced Research Projects Agency’s Biological Technologies Office, guiding an investment portfolio across biodefense, novel medicine development, and biomanufacturing to protect the nation while advancing groundbreaking scientific capabilities. She has served as a Senate policy advisor, as well as co-founder, Board Member, and advisor of several biotech and health startups, including OOVA, ImmuneBridge, and Drawbridge Health.
Dr. Jackson holds a Ph.D. in materials science from the Massachusetts Institute of Technology.
Introducing Alina Su, founder and CEO of Generation Lab, the fastest-growing AI longevity company. Previously from Harvard Medical School, she co-founded Generation Lab with Dr. Irina Conboy — “the mother of longevity” who invented blood exchange from UC Berkeley Conboy Lab. Backed by tier 1 VCs like Accel and Samsung, Generation Lab created SystemAge, the world’s most accurate organ biological age test, with a personalized longevity plan. And now they are developing an injection shot that makes you young replacing blood exchange.
Already trusted by over 500 leading clinics worldwide and Hollywood A list celebrities from Kim Kardashian to Zac Efron, Naval Ravikant NBA NFL players — Generation Lab is creating the Ageless generation.
Dr. Tornatore is the Regional Chief of Neurology for MedStar Health and Chairman and Neurologist-in-Chief in the Department of Neurology at MedStar Georgetown University Hospital. He is also the Executive Director of the Multiple Sclerosis Patient Centered Specialty Practice MedStar Georgetown and Professor and Chairman in the Department of Neurology at Georgetown University Medical Center. Dr. Tornatore received his undergraduate degree in neurobiology from Cornell University and then attended Georgetown University School of Medicine where he received his medical degree. Following a Neurology Residency at Georgetown University Hospital, he was a post-doctoral fellow at the National Institute of Neurologic Disorders and Stroke at the National Institutes of Health. Dr. Tornatore has published extensively in the areas of neuroimmunology, neurovirology and Multiple Sclerosis and is currently involved in over 15 clinical trials for the treatment of Multiple Sclerosis. He has won multiple awards in the areas of medical student teaching, patient care and scholarly research.
